Molina-Ramos, Ana IGomez-Moyano, ElisabethRodriguez-Capitan, JorgeAngullo-Gomez, MariaGallardo-Jimenez, PatriciaPerez-de-Pedro, IvanValiente-de-Santis, LuciaPerez-Villardon, BeatrizPiñero-Uribe, IsabelMora-Robles, JavierBecerra-Muñoz, Victor ManuelJimenez-Navarro, Manuel2023-05-032023-05-032022-11-26Molina-Ramos AI, Gómez-Moyano E, Rodríguez-Capitán J, Angullo-Gómez M, Gallardo-Jiménez P, Pérez de Pedro I, et al. Myocarditis Related to COVID-19 and SARS-CoV-2 Vaccination. J Clin Med. 2022 Nov 26;11(23):69992077-0383http://hdl.handle.net/10668/21365The coronavirus disease of 2019 (COVID-19) has been a cause of significant morbidity and mortality worldwide. Among the short- and long-term consequences of COVID-19, myocarditis is a disease to be taken into consideration. Myocarditis, in general, is related to a poor prognosis. However, the epidemiology and prognosis of myocarditis related to COVID-19 are currently unknown. While vaccination against COVID-19 is of great benefit at a public health level, the risk of myocarditis should be considered in the context of the global benefits of vaccination. In this narrative review, we will summarize the etiopathogenic bases, the epidemiology, the clinical manifestations, the course, diagnosis, prognosis, and the treatment of myocarditis related to SARS-CoV-2, as well as myocarditis secondary to mRNA vaccines.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/COVID-19mRNA vaccinesMyocarditisSARS-CoV-2PrognosisVaccinationHealth StatusMyocarditis Related to COVID-19 and SARS-CoV-2 Vaccination.research article36498573open accessMiocarditisEpidemiologíaSARS-CoV-2CoronavirusSalud públicaVacunas de ARNm10.3390/jcm11236999PMC9738968https://www.mdpi.com/2077-0383/11/23/6999/pdf?version=1670205463https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738968/pdf